CASI Pharmaceuticals
CASI
CASI was delisted on the 25th of February, 2026.
23 hedge funds and large institutions have $1.94M invested in CASI Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 4 closing their positions.
113% more capital invested
Capital invested by funds: $910K → $1.94M (+$1.03M)
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
15% more funds holding
Funds holding: 20 → 23 (+3)
0.74% more ownership
Funds ownership: 1.89% → 2.63% (+0.74%)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
+$347K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$35.2K |
| 3 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$25.6K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$21.4K |
| 5 |
Renaissance Technologies
New York
|
+$12.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Howland Capital Management
Boston,
Massachusetts
|
-$78.8K |
| 2 |
Wells Fargo
San Francisco,
California
|
-$35.7K |
| 3 |
WSCM
Wellington Shields Capital Management
New York
|
-$9.32K |
| 4 |
CFM
Catalyst Funds Management
Sydney NSW,
Australia
|
-$5.6K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.8K |
CASI Hedge Fund Activity: Q2 2024 in Review
23 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q2 2024, worth a combined $1.94M — up 113% from $910K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new CASI positions and 4 closed out — a net gain of 3 holders — while 3 added to existing stakes and 4 trimmed.
The largest buyer was VR Adviser, opening a new position worth an estimated $347K. The largest seller was Howland Capital Management, cutting an estimated $78.8K.
- 23 institutional investors held CASI Pharmaceuticals (CASI) as of Q2 2024, up from 20 in Q1 2024.
- Funds reported $1.94M of CASI Pharmaceuticals stock for Q2 2024, up 113% quarter-over-quarter.
- 7 funds opened new CASI Pharmaceuticals positions in Q2 2024 and 4 closed out, a net change of +3 holders.
- The largest CASI Pharmaceuticals buyer in Q2 2024 was VR Adviser, an estimated $347K added.
- The largest CASI Pharmaceuticals seller in Q2 2024 was Howland Capital Management, an estimated $78.8K sold.
Based on aggregated 13F filings for Q2 2024.